Abstract: A method for predicting transplant-free survival of a patient suffering from acute liver failure (ALF) or acute liver injury (ALI), the method including: performing a 13C-methacetin breath test which includes administering 13C labelled methacetin to the patient; measuring exhaled breath to evaluate changes in a 13CO2 to 12CO2 ratio for a predetermined time after the administering; calculating a PDR-peak value of the patient; and predicting the patient as having high chances of transplant-free survival if the calculated PDR-peak value is above a threshold value or as having low chances of transplant-free survival if the PDR-peak value is below threshold value.

Abstract: Disclosed is a method for predicting a decompensation event in a patient suffering from NASH, including performing a 13C methacetin breath test on a patient; calculating a PDR-peak value of the patient, based on the 13C methacetin breath test; and identifying the patient as having high-risk of developing a decompensation event within 1 year from the performing of the breath test, if the PDR-peak value is at or below a predetermined threshold value; wherein the predetermined threshold value is 15%/h.

Abstract: There is provided a method of evaluating a liver condition of a subject, the method includes computing a fluctuation parameter from a liver breath test based on at least one of a percentage dose recovery (PDR) curve and a delta over baseline (DOB) curve of an isotope labeled methacetin, or a salt or a derivative thereof, and evaluating at least one liver condition of the subject, based at least on the fluctuation parameter. There is provided herein a method of evaluating a liver condition of a subject, the method includes computing a hepatic impairment score based at least on a breath test related parameter and on a demographic parameter.

Abstract: There is provided a method of evaluating a liver condition of a subject, the method includes computing a fluctuation parameter from a liver breath test based on at least one of a percentage dose recovery (PDR) curve and a delta over baseline (DOB) curve of an isotope labeled methacetin, or a salt or a derivative thereof, and evaluating at least one liver condition of the subject, based at least on the fluctuation parameter. There is provided herein a method of evaluating a liver condition of a subject, the method includes computing a hepatic impairment score based at least on a breath test related parameter and on a demographic parameter.

Abstract: Methods and systems for diagnosis, prognosis and monitoring of hepatocellular carcinoma (HCC). Specifically, the present invention relates to the use of breath tests based on isotope-labeled octanoate in the detection and monitoring of HCC.

Abstract: Methods and systems for diagnosis, prognosis and monitoring of hepatocellular carcinoma (HCC). Specifically, the present invention relates to the use of breath tests based on isotope-labeled octanoate in the detection and monitoring of HCC.

Abstract: There is provided herein a method and a device for measuring, using one or more breath sensors, a metabolic product of a fatty acid, a salt or a derivative thereof, in the subject's breath after administering to the subject an isotope labeled fatty acid, a salt or a derivative thereof, obtaining the subject's level of insulin, glucose, glucagon or a combination thereof and using a processing circuitry, evaluating the liver condition based on the subject's metabolic product of the fatty acid, salt or derivative thereof and the level of insulin, glucose, glucagon or a combination thereof.

Abstract: The present invention relates to methods and systems for diagnosis, prognosis and monitoring of hepatocellular carcinoma (HCC). Specifically, the present invention relates to the use of breath tests based on isotope-labeled octanoate in the detection and monitoring of HCC.

Abstract: The present invention relates to methods and systems for diagnosis, prognosis and monitoring of hepatocellular carcinoma (HCC). Specifically, the present invention relates to the use of breath tests based on isotope-labeled octanoate in the detection and monitoring of HCC.

Abstract: There is provided a method of evaluating a liver condition of a subject, the method includes computing a fluctuation parameter from a liver breath test based on at least one of a percentage dose recovery (PDR) curve and a delta over baseline (DOB) curve of an isotope labeled methacetin, or a salt or a derivative thereof, and evaluating at least one liver condition of the subject, based at least on the fluctuation parameter. There is provided herein a method of evaluating a liver condition of a subject, the method includes computing a hepatic impairment score based at least on a breath test related parameter and on a demographic parameter.

Abstract: The disclosure relates to breath test devices and methods for the evaluation of liver functional and metabolic capacity or to assess liver heath and/or degree of liver injury. Specifically, there is provided a method of evaluating a liver condition, the method includes on-line monitoring a metabolic product of methacetin, a salt or a derivative of methacetin, in a subject's breath after administering to the subject isotope labeled methacetin, a salt or a derivative thereof in water solution form. There is also provided a device for evaluating a liver condition, the device includes one or more sensors adapted to monitor on-line an isotope level of a metabolic product of labeled methacetin, or a salt or a derivative of methacetin in a subject's breath and a controller adapted to sample measurements of the one or more sensors at a continuous mode.

Abstract: There is provided a method of evaluating a liver condition of a subject, the method includes computing a fluctuation parameter from a liver breath test based on at least one of a percentage dose recovery (PDR) curve and a delta over baseline (DOB) curve of an isotope labeled methacetin, or a salt or a derivative thereof, and evaluating at least one liver condition of the subject, based at least on the fluctuation parameter. There is provided herein a method of evaluating a liver condition of a subject, the method includes computing a hepatic impairment score based at least on a breath test related parameter and on a demographic parameter.

Abstract: There is provided a method of evaluating a liver condition of a subject, the method includes computing a fluctuation parameter from a liver breath test based on at least one of a percentage dose recovery (PDR) curve and a delta over baseline (DOB) curve of an isotope labeled methacetin, or a salt or a derivative thereof, and evaluating at least one liver condition of the subject, based at least on the fluctuation parameter. There is provided herein a method of evaluating a liver condition of a subject, the method includes computing a hepatic impairment score based at least on a breath test related parameter and on a demographic parameter.